NCT00506077View on ClinicalTrials.gov

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Paranoid Schizophrenia
Interventions
DRUG

MK0249

MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.

DRUG

Comparator: Placebo (unspecified)

MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00506077 - MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) | Biotech Hunter | Biotech Hunter